Please Welcome

Changing Lives Through Research

Dang Laboratory Explores
Novel Approaches to
Diagnosing, Treating
Liver Cancer
Drs. William Preston, Madison Crutcher, Robert Kucejko, and Darshak Thosani

Jefferson Welcomes Four Surgery
Residents from Hahnemann

The Dang Laboratory, located at 603 College Building, is dedicated to studying Hepatocellular Carcinoma (HCC).
The laboratory team, led by Hien Dang, PhD (center), includes Anna Barry, MS, and Kai Zhang, PhD.

Since its launch on October 1, 2018,
the Dang Laboratory has been
dedicated to the study of novel
approaches to diagnosing and treating
hepatocellular carcinoma (HCC), the
most common type of liver cancer.
The lab, which is part of the Division
of Surgical Research, recently secured
two grants and is led by Hien Dang,
PhD, with support from Postdoctoral
Fellow Kai Zhang, PhD, and Lab
Technician Anna Barry, MS.
Before joining the faculty at Jefferson,
Dr. Dang worked as a Postdoctoral
Fellow supported by a Cancer
Research Training Award (CRTA) at
the National Cancer Institute, National
Institutes of Health in Bethesda,
Maryland. While there, she worked
in the Laboratory of Human
Carcinogenesis in the Center for
Cancer Research. At Jefferson,
she and her team collaborate with
Jefferson surgeons Ashesh P. Shah,
MD, Adam S. Bodzin, MD, and Warren
Maley, MD, as well as James A. Posey,
MD, of Medical Oncology. These
collaborations are key to enabling
the research, as well as applying the
findings to clinical decision making.
“Most of the work we do has clinical
implications,” Dr. Dang says. “In other
words, does it make sense to triage
liver cancer patients into specific
subtypes? Does it make sense to
include biomarkers for picking out
subtypes and unique subgroups?
When a patient isn’t eligible for a
liver transplant, how can we best
treat them?”

The Dang Laboratory’s two most
recent grants are from the American
Liver Foundation and the American
Cancer Society. The first is supporting
work to identify specific lethal targets
based on the biology of a patient’s
tumor.
“The grant covers development of
a platform to use in the clinic to
subtype the patient – that is, to take
a piece of tissue and say, ‘Here’s the
genomics. Based on that, the patient
belongs to this subtype, and,
therefore, this drug will work best,’”
Dr. Dang says.

When Hahnemann Hospital announced
at the end of June that it was closing its
doors, 571 residents and fellows were
suddenly facing an uncertain future. By
July 5, the Thomas Jefferson University
Department of Surgery had conducted
interviews with 18 soon-to-be-displaced
residents and extended invitations
to four: William Preston, MD (PGY1),
Darshak Thosani, MD (PGY2), Madison
Crutcher, MD (PGY3) and Robert
Kucejko, MD (PGY4). All four accepted
and are now active members of the
Jefferson surgery program.
“We had been hearing rumors about
Hahnemann for at least 15 years,
so the closure wasn’t a complete
shock,” explains Residency Program
Coordinator Donna Guinto. “However,
it is highly unusual for residents to

The second grant is enabling the lab
to delve into something even more
novel: proteins that form aggregates.
Sometimes RNA-binding proteins
come together to form aggregates
rather than remaining independent
and fulfilling their own function.
Such protein aggregates play a key
role in diseases, such as Parkinson’s,
and Dr. Dang and her team’s
hypothesis is that these aggregates
could play a big part in fueling liver
cancer.

found evidence to the contrary –
that micro-RNAs may not actually
kill cancer cells. Preliminary findings
suggest that RNA-binding proteins
can independently regulate RNA
transcription. In other words, at best

“This study is a big deal – something
no one else has tackled before,”
she notes.
In addition to the American Cancer
Society-funded research, the lab has
been studying another aspect of
protein aggregates. Dr. Dang explains
that the current paradigm is that
micro-RNAs regulate RNAs and,
therefore, micro-RNAs can be pivotal
in targeting cancer cells. Her team has

“Understanding the
genomics, or biology,
of a tumor is invaluable
in helping determine
the right course of
treatment.”
using micro-RNAs to treat cancer
could be ineffective; at worst, it
could be fueling cancer cells. For yet
another project, they are exploring
whether protein aggregates are
found in actual patient tissues versus

move to a new institution. The last time
we hired a displaced resident was when
St. Vincent’s Hospital in New York City
closed in 2010.”
Guinto praises all four residents for
making a smooth transition to Jefferson.
She notes that the ability to stay in
Philadelphia was very beneficial for all
of them. That was especially true for
Dr. Crutcher, whose significant other
was also a Hahnemann resident (he
found a new home at Cooper University
in New Jersey).
“Everyone has been very nice and
welcoming,” says Dr. Crutcher.
“Jefferson got us started as soon as
possible so there has been no disruption
in our training.”

cell models – and whether those
aggregates can be used to predict
therapy response and/or survival.
The continued work of the Dang
Laboratory is helping to inform
treatment for all liver cancer
patients – whether treated with
surgery, chemotherapy, radiation
or some combination.
“Understanding the genomics, or
biology, of a tumor is invaluable in
helping determine the right course
of treatment,” she concludes.

For more information about the
Dang Laboratory, please visit:
Jefferson.edu/DangLab

For an appointment with a Jefferson Surgeon, call 1- 800-JEFF-NOW

